Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Genitourinary Cancers Symposium
1 in 5 US Clinical Trials Fails to Complete
By
Phoebe Starr
Genitourinary Cancers Symposium
February 2014, Vol 5, No 1
San Francisco, CA—The early termination of clinical trials is a tremendous waste of resources and can leave patients with cancer with no improved treatment options.
Read Article
Adding Radiation to Antiandrogen Hormone Therapy Extends Survival in Patients with High-Risk Prostate Cancer
By
Phoebe Starr
Genitourinary Cancers Symposium
February 2014, Vol 5, No 1
San Francisco, CA—Radiation added to hormone therapy with antiandrogens extended cancer-specific survival, as well as overall survival, when used as the primary treatment of patients with locally advanced or high-risk prostate cancer.
Read Article
Angiotensin System Inhibitors Extend Survival in Patients with Metastatic Renal-Cell Carcinoma
By
Phoebe Starr
Genitourinary Cancers Symposium
February 2014, Vol 5, No 1
San Francisco, CA—The use of angiotensin system inhibitors (ASIs) improved survival in patients with metastatic renal-cell carcinoma (mRCC) by 9 months, according to a retrospective pooled analysis of several clinical trials presented at the 2014 Genitourinary Cancers Symposium.
Read Article
Enzalutamide Extends Survival in Previously Untreated Metastatic Prostate Cancer
By
Phoebe Starr
Genitourinary Cancers Symposium
February 2014, Vol 5, No 1
San Francisco, CA—Enzalutamide (Xtandi) prolonged survival and delayed radiographic progression of disease in men who had not received chemotherapy for metastatic castration-resistant prostate cancer (mCRPC).
Read Article
External Beam Radiation More Toxic, Costlier than Brachytherapy or Prostatectomy
By
Wayne Kuznar
Genitourinary Cancers Symposium
March 2012, Vol 3, No 2
San Francisco, CA—In a retrospective long-term comparative analysis of 3 prostate cancer treatment strategies, treatment with external beam radiation therapy (EBRT) was more toxic and costlier than prostatectomy and brachytherapy, according to Cleveland Clinic researchers who presented their data at the 2012 annual Genitourinary Cancers Symposium.
Read Article
Personalized Vaccine Promising When Added to Sunitinib in Patients with Metastatic Renal-Cell Carcinoma
By
Wayne Kuznar
Genitourinary Cancers Symposium
March 2012, Vol 3, No 2
San Francisco, CA—A personalized form of immunotherapy added to sunitinib (Sutent) treatment prolonged survival to beyond 30 months in almost half of patients with newly diagnosed, unfavorable-risk metastatic renal-cell carcinoma (mRCC), according to the results of an open-label phase 2 study presented at the 2012 Genitourinary Cancer Symposium.
Read Article
Dose Escalation of Axitinib as Second-Line Treatment of mRCC May Be Needed to Optimize Outcome
By
Wayne Kuznar
Genitourinary Cancers Symposium
March 2012, Vol 3, No 2
San Francisco, CA—The dosage of axitinib, the standard second-line treatment for metastatic renal-cell carcinoma (mRCC), should be uptitrated in those patients who fail to achieve therapeutic blood levels on the standard 5-mg daily dosage, according to a new analysis of an international randomized trial presented at the 2012 Genitourinary Cancers Symposium.
Read Article
A Large Subset of Patients with Metastatic Prostate Cancer Go Untreated
Genitourinary Cancers Symposium
March 2012, Vol 3, No 2
San Francisco, CA—More than 1 in 10 patients with metastatic prostate cancer never receive anticancer treatment for their disease, according to an examination of the National Cancer Database.
Read Article
Many Patients with mRCC Ineligible for Clinical Trials
By
Wayne Kuznar
Genitourinary Cancers Symposium
March 2012, Vol 3, No 2
San Francisco, CA—A large number of patients with metastatic renal-cell carcinoma (mRCC) are ineligible for clinical trials and their clinical outcomes are inferior to those of patients who are trial eligible, according to a study presented at the 2012 Genitouri nary Cancers Symposium.
Read Article
Nonpharmacologic Strategies Have Mixed Results in Prostate Cancer Prevention
By
Phoebe Starr
Genitourinary Cancers Symposium
March 2012, Vol 3, No 2
San Francisco, CA—Nonpharmacologic strategies for prevention of cancer are potentially attractive and costeffective, but success stories are few.
Read Article
Page 2 of 4
1
2
3
4
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma